A5081099308- SARS-CoV-2 and COVID-19 Research
- COVID-19 Clinical Research Studies
- Viral Infections and Outbreaks Research
- SARS-CoV-2 detection and testing
- Respiratory viral infections research
- Mosquito-borne diseases and control
- Virus-based gene therapy research
- Viral gastroenteritis research and epidemiology
- Bacterial Infections and Vaccines
- RNA and protein synthesis mechanisms
- COVID-19 diagnosis using AI
- Malaria Research and Control
- Influenza Virus Research Studies
- Hepatitis B Virus Studies
- Long-Term Effects of COVID-19
- Transgenic Plants and Applications
- Pediatric health and respiratory diseases
- Viral Infections and Vectors
- Pneumonia and Respiratory Infections
- Immune Response and Inflammation
- Immunotherapy and Immune Responses
- Hepatitis Viruses Studies and Epidemiology
- vaccines and immunoinformatics approaches
- Immune Cell Function and Interaction
Instituto de Investigación Nutricional
2012-2024
Janssen (Netherlands)
2019-2024
Johnson & Johnson (Netherlands)
2024
Springer Nature (Germany)
2016
Sanofi (France)
2016
Asociación Colombiana de Infectología
2016
Institut Pasteur de Montevideo
2016
Sanofi (United States)
2016
Safe and effective coronavirus disease–19 (COVID-19) vaccines are urgently needed to control the ongoing pandemic. While single-dose vaccine regimens would provide multiple advantages, two doses may improve magnitude durability of immunity protective efficacy. We assessed one- two-dose Ad26.COV2.S candidate in adult aged nonhuman primates (NHPs). A regimen induced higher peak binding neutralizing antibody responses compared with a single dose. In one-dose regimens, were stable for at least...
Previously we have shown that a single dose of recombinant adenovirus serotype 26 (Ad26) vaccine expressing prefusion stabilized SARS-CoV-2 spike antigen (Ad26.COV2.S) is immunogenic and provides protection in Syrian hamster non-human primate infection models. Here, investigated the immunogenicity, protective efficacy, potential for vaccine-associated enhanced respiratory disease (VAERD) mediated by Ad26.COV2.S moderate challenge model, using currently most prevalent G614 variant. Vaccine...
Respiratory Syncytial Virus (RSV) can cause severe respiratory disease, yet a licensed vaccine is not available. We determined the immunogenicity of two homologous and one heterologous intramuscular prime-boost vaccination regimens using replication-incompetent adenoviral vectors human serotype 26 35 (Ad26 Ad35), expressing prototype antigen based on wild-type fusion (F) protein RSV strain A2 in adult, RSV-naive cynomolgus macaques. All induced substantial, boostable antibody responses that...
This trial assessed the safety of a fully liquid investigational hexavalent DTaP-IPV-Hep B-PRP-T vaccine containing 10 μg Hansenula polymorpha-derived recombinant hepatitis B (hep B) antigen for primary vaccination infants at 2, 4 and 6 months age compared with licensed comparators.Participants received (group 1, N = 1422) or DTwP-Hep B//Hib (Tritanrix-Hep B/Hib) oral poliovirus vaccines 711). The incidence severe fever (≥ 39.6°C rectal equivalent) in 2 groups was statistically;...
Dengue and yellow fever (YF) viruses are closely related members of the Flaviviridae family. Given inherent similarities between YF vaccine dengue (CYD-TDV) candidate, it is possible that latter could interfere with response to licensed when coadministered.In this randomized, observer-blind, controlled, phase III trial, conducted in Colombia Peru, 787 toddlers were administered concomitantly CYD-TDV (group 1) or placebo 2), followed by after 6 12 months. neutralizing antibody titers...
The adenovirus (Ad)26 serotype-based vector vaccine Ad26.COV2.S has been used in millions of subjects for the prevention COVID-19, but potentially elicits persistent anti-vector immunity. We investigated if vaccine-elicited immunity to Ad26 vector-based vaccines significantly influences antigen-specific immune responses induced by a subsequent vaccination with regimens against different disease targets non-human primates. A homologous regimen or heterologous (Ad26/Ad35 Ad26/Modified Vaccinia...
Abstract Safe and effective coronavirus disease (COVID)-19 vaccines are urgently needed to control the ongoing pandemic. While single-dose vaccine regimens would provide multiple advantages, two doses may improve magnitude durability of immunity protective efficacy. We assessed one- two-dose Ad26.COV2.S candidate in adult aged non-human primates (NHP). A regimen induced higher peak binding neutralizing antibody responses compared a single dose. In one-dose were stable for at least 14 weeks,...
Abstract Since the original outbreak of SARS-CoV-2 virus, several rapidly spreading variants concern (VOC) have emerged. Here, we show that a single dose Ad26.COV2.S (based on Wuhan-Hu-1 spike variant) protects against Gamma and Delta in naive hamsters, supporting observed maintained vaccine efficacy humans these VOC. Adapted spike-based booster vaccines targeting Omicron now been authorized absence human data. We evaluated immunogenicity Ad26.COV2.S.529 (encoding stabilized BA.1 spike) mice...
Abstract Seasonal influenza vaccines must be updated annually and suboptimally protect against strains mismatched to the selected vaccine strains. We previously developed a subunit antigen consisting of stabilized trimeric A group 1 hemagglutinin (H1) stem protein that elicits broadly neutralizing antibodies. Here, we further optimized stability manufacturability H1 (H1 v2, also known as INFLUENZA G1 mHA) characterized its formulation potency with different adjuvants in vitro animal models....
<title>Abstract</title> Given the local and systemic adverse reactions associated with whole cell pertussis vaccines combined diphtheria tetanus toxoids (DTP), acellular same (DTaP) were developed in 1990s. In comparison to DTP, DTaP demonstrated reduced reactogenicity equivalent or improved immunogenicity efficacy. However, there has been a resurgence of disease, particularly DTaP-vaccinated children, suggesting that immunity wanes more quickly vaccination. To elucidate differences immune...
Human metapneumovirus (HMPV) is a significant respiratory pathogen, particularly in vulnerable populations. No vaccine for the prevention of HMPV currently licensed, although several subunit vaccines are development. Saponin-based adjuvant systems (AS), including QS-21, have transformed field by dramatically increasing their potency and efficacy, leading to development licensed vaccines. However, naturally sourced tree bark-extracted QS-21 faces supply manufacturing challenges, hindering...
ABSTRACT Previously we have shown that a single dose of recombinant adenovirus serotype 26 (Ad26) vaccine expressing prefusion stabilized SARS-CoV-2 spike antigen (Ad26.COV2.S) is immunogenic and provides protection in Syrian hamster non-human primate infection models. Here, investigated the immunogenicity, protective efficacy potential for vaccine-associated enhanced respiratory disease (VAERD) mediated by Ad26.COV2.S moderate challenge model, using currently most prevalent G614 variant....
Abstract The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron variant sparked concern due to its fast spread and the unprecedented number of mutations in spike protein that enables it partially evade spike-based COVID-19 vaccine-induced humoral immunity. In anticipation a potential need for an vaccine, we generated Ad26 vector encoding (BA.1) (Ad26.COV2.S.529). Ad26.COV2.S.529 encodes prefusion stabilized protein, similar current vaccine Ad26.COV2.S Wuhan-Hu-1 protein. We...